A Phase 2 Single Arm Trial of Stereotactic Body Radiation Therapy Followed by Dual Immune Checkpoint Inhibition for Patients With Metastatic Pancreatic Ductal Adenocarcinoma - The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation
Latest Information Update: 01 Jul 2025
At a glance
- Drugs Botensilimab (Primary) ; Balstilimab
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms EMPIRE
Most Recent Events
- 25 Jun 2025 Status changed from not yet recruiting to recruiting.
- 06 Jun 2025 Planned End Date changed from 1 Jun 2030 to 1 Aug 2030.
- 06 Jun 2025 Planned primary completion date changed from 1 Jun 2030 to 1 Aug 2030.